Orthocell Limited Seeks ASX Quotation for 15,430 Shares Issued as Director Fee Adjustment Under Employee Awards Plan

Overview of Orthocell's Employee Awards Plan and Director Remuneration

Orthocell Limited administers an Employee Awards Plan aimed at aligning directors’ and key executives’ interests with those of shareholders via equity-based compensation. The issuance of 15,430 shares constitutes an adjustment to director fee shares under this plan, which shareholders approved at the 2025 annual general meeting. This plan enables the company to remunerate directors partially through shares instead of cash, fostering a direct connection between management compensation and shareholder value creation. Such equity-based incentive schemes are common governance practices among ASX-listed companies to retain talent and align executives with long-term strategic goals.

This director fee share adjustment underscores Orthocell’s commitment to a transparent, shareholder-approved remuneration framework. Utilizing the Employee Awards Plan for director compensation reduces cash outflows while granting directors a vested economic interest in company performance. The issuance, approved previously and now formalized via ASX quotation application, reflects the company’s systematic approach to executing authorized remuneration decisions.

Details of the 15,430 Share Issuance and Pricing

Orthocell has applied to quote 15,430 ordinary fully paid shares issued on 20 July 2026 at AUD 0.75610000 per share. Denominated in Australian dollars, these shares augment the company’s quoted share capital. The issue price reflects the market value at issuance, illustrating the timing of the director fee adjustment amid mid-July 2026 market conditions. This price represents the consideration credited against the director fee adjustment approved by shareholders, ensuring transparency between compensation and economic value.

The newly issued shares rank equally with existing ordinary shares from the issue date, carrying identical voting rights, dividend entitlements, and economic benefits. This equal ranking prevents preferential treatment among shareholders. Quotation on the ASX enhances liquidity and transparency concerning the director fee arrangement, allowing market participants to track the issuance alongside other company securities.

Capital Structure Post-Quotation and Regulatory Compliance

Following the quotation of these shares, Orthocell’s total quoted capital on the ASX will be 272,269,067 ordinary fully paid shares, representing the company’s core capital base. Additionally, Orthocell holds 18,650,913 unquoted securities comprising options, retention rights, and performance rights. Options have exercise prices ranging from AUD 0.36 to AUD 1.95 and expiry dates between April 2027 and October 2028, offering the company flexibility in equity management and employee retention strategies.

The unquoted securities include 3,218,617 retention rights, typically used to promote long-term employee commitment, and 1,947,696 performance rights linked to corporate milestone achievements. This diverse portfolio indicates Orthocell’s multi-dimensional approach to incentivizing employees beyond cash or ordinary shares. The staggered expiry dates suggest a rolling equity grant program spanning multiple years, creating predictable dilution events for stakeholders to consider.

Regulatory Framework and Listing Rule Compliance

The 15,430 share issuance qualifies under exception 14 of Listing Rule 7.2, exempting it from requiring additional shareholder approval under Listing Rule 7.1. This classification applies to shares issued pursuant to employee share schemes approved by shareholders, consistent with Orthocell’s 2025 annual general meeting approval.

No prior market announcement via Appendix 3B was made, indicating this issuance is a pre-planned, routine execution of previously approved arrangements. The Appendix 2A application for quotation serves as formal market notification, ensuring transparency and providing stakeholders with definitive information on the director fee adjustment once shares are listed.

Company Background and Market Position

Orthocell Limited (ACN 118897135) is an ASX-listed healthcare and biotechnology company specializing in cellular medicine and regenerative therapies. While specific financial or production data is not disclosed in this update, the structured Employee Awards Plan and regular equity issuances to directors indicate an established operational and management framework. The layered options and performance rights programs suggest ongoing capital raising to support research, development, and commercialization activities.

Compensating directors partially with equity reflects confidence in long-term value growth and aligns with governance best practices in biotech and healthcare sectors. The multiple option tranches with varied exercise prices and expiry dates reveal several capital management initiatives aimed at incentivizing different employee groups and achieving strategic goals. The combination of retention and performance rights highlights a sophisticated talent management strategy that balances loyalty incentives with performance-based rewards.

Issued Capital and Unquoted Securities Breakdown

Orthocell’s unquoted securities portfolio is substantial, complementing its 272,269,067 quoted ordinary shares. Major option tranches include 4,000,000 options expiring 29 May 2028 at AUD 0.40, 3,240,000 options expiring 19 April 2027 at AUD 0.36, and 3,000,000 options expiring 31 October 2027 at AUD 0.67. Additional tranches include 3,000,000 options expiring 8 March 2028 at AUD 0.40 and 2,000,000 options across various exercise prices. This diversified options portfolio creates potential dilution scenarios depending on future share price movements.

Retention rights total 3,218,617 units, and performance rights account for 1,947,696 units. Retention rights typically vest over time to secure ongoing employment, while performance rights convert upon achieving defined financial or strategic milestones. Together, these represent approximately 1.2% and 0.7% respectively of the quoted share capital, underscoring Orthocell’s emphasis on long-term employee retention and performance incentives as vital components of its human capital strategy.

Timeline and Execution of Director Fee Share Adjustment

Shareholders approved the director fee share adjustment at the 2025 annual general meeting, establishing the governance basis for issuance. The 15,430 shares were issued on 20 July 2026, with the company applying for ASX quotation the same day. This prompt coordination reflects efficient administrative execution, minimizing delay between share creation and formal listing.

The July 2026 issuance likely aligns with governance schedules, director fee payment cycles, or internal administrative timing. The AUD 0.75610000 issue price corresponds to prevailing mid-July 2026 market conditions. Investors should note that this director fee adjustment is now formalized and becoming part of Orthocell’s official quoted share register, rendering the shares fully tradable under standard market liquidity conditions.

Market Impact and Investor Considerations

The immediate impact on share price is not publicly available. The 15,430 shares represent approximately 0.0057% of Orthocell’s post-issuance quoted capital, indicating minimal dilution from this tranche. However, investors should consider this issuance within the context of the 18,650,913 unquoted securities, which may contribute to incremental dilution as options are exercised or performance rights vest over time. This staggered dilution may spread share price effects across multiple years.

For investors evaluating Orthocell’s capital management, this director fee adjustment is a routine implementation of approved remuneration rather than a strategic capital raise. The relatively small size of this issuance should be distinguished from potential future equity raises or large-scale option exercises with more significant share price implications. Monitoring future Appendix 2A or 3B filings will help investors track ongoing capital activities and cumulative dilution.

Governance and Shareholder Engagement

Orthocell’s director compensation via the Employee Awards Plan reflects a governance model prioritizing transparency and shareholder participation. Shareholder approval at the annual general meeting for the director fee share mechanism demonstrates respect for shareholder rights and adherence to governance standards. Listing Rule 7.2 exception 14 recognizes approved employee share schemes as a distinct issuance category exempt from repeated shareholder approval, balancing administrative efficiency with oversight.

Prompt ASX quotation applications and detailed disclosures via Appendix 2A highlight Orthocell’s commitment to market transparency and continuous disclosure compliance. This reporting enables stakeholders to monitor capital structure changes and understand equity issuance purposes. The structured use of approved employee share schemes combined with timely market notification exemplifies a governance approach that fosters investor confidence in orderly capital management.